For the past decade, cardiac safety screening to evaluate the propensity of drugs to produce
QT interval prolongation and Torsades de Pointes (TdP) arrhythmia has been conducted …

A number of non‐cardiovascular drugs have been withdrawn from clinical use due to
unacceptable adverse cardiac side‐effects involving drug‐induced Torsades de Pointes (TdP) – a …

Given that cardiovascular safety concerns remain the leading cause of drug attrition at the
preclinical drug development stage, the National Center for Toxicological Research of the US …

Cardiovascular toxicity, a prominent reason for late-stage failures in drug development, has
resulted in a demand for in vitro assays that can predict this liability in early drug discovery. …

Functional changes to cardiomyocytes are a common cause of attrition in preclinical and
clinical drug development. Current approaches to assess cardiomyocyte contractility in vitro are …

Rationale: Spontaneous Ca 2+ release (SCR) from the sarcoplasmic reticulum can cause
delayed afterdepolarizations and triggered activity, contributing to arrhythmogenesis during β-…

Introduction Detection of drug-induced pro-arrhythmic risk is a primary concern for pharmaceutical
companies and regulators. Increased risk is linked to prolongation of the QT interval …

Introduction Unwanted drug interactions with ionic currents in the heart can lead to an
increased pro-arrhythmic risk to patients in the clinic. It is therefore a priority for safety …

In vivo studies have suggested that increased beat-to-beat variability of ventricular
repolarization duration (BVR) is a better predictor of drug-induced torsades de pointes than …

Morphological damage to cardiomyocytes or loss of viability (structural cardiotoxicity) is a
common cause of attrition in preclinical and clinical drug development. Currently, no predictive …